Lidco Share Discussion Threads

[buywell2] 04/3/2019 03:09

THREAD CLOSED

[gbenson1] 03/3/2019 12:24

Buywell or should I say cut n paste man? Your deluded if you think anyone would solely base their buying of shares on what they read on these boards, some times it's worse than the beano!!

[7767] 01/3/2019 18:26

said distressed not a losing faith investor

[mrc2u] 01/3/2019 18:17

Agree that these are cheap. But they have only fallen by a quarter on back to back profit warnings one on each side of year end so they could go down further still if a big holder has lost the faith. Needs an upbeat statement on current year trading when they put results out in less than 4 weeks. In meantime might buy at 2.5p.Buywell, outside UK, the only competition that matters is Edwards hence HUP price cutting. Edwards are massive with very deep pockets so LID need to avoid a war.MrC

[7767] 01/3/2019 17:46

It appears there is a distressed seller and mm's placing their shares, no reflection of company so great price to buy while it this silly level IMHO.

[buywell2] 01/3/2019 17:07

POST REMOVED

[gbenson1] 01/3/2019 13:00

I'm a holder here and in DEMG, I disagree that the company's in good shape, why would someone sell 1m+ at the 12 month low in the Sp?

[7767] 01/3/2019 12:35

It appears there is a distressed seller and mm's placing their shares, no reflection of company so great price to buy while it this silly level IMHO.

[buywell2] 22/2/2019 19:30

POST REMOVED

[arf dysg] 22/2/2019 10:27

"Overall, LiDCO product revenues for FY19 were GBP6.19m (FY18: GBP6.87m)
[...]
we are well-placed to grow the business"



As long as your revenues and profits are smaller than infinity, you could potentially grow the business.



Is there anyone out there who could do with another probe?

Apparently, Area 51 in Nevada is the place. If LiDCO's customers have had any strange encounters with aliens, perhaps they've already had a probe, in a manner of speaking. If they enjoyed it, they may even come back for more.

[buywell3] 20/2/2019 19:27

IMO the renewal of sales to China , which should commence in a few months , will add circa 1M turnover to LIDCO in the coming year. Revenue recognition from HUP contracts both in the UK and USA and elsewhere should also show in the next years numbers.

Added to that newer and better 3rd party products have recently been added on better margins than existed with Argon, I expect an improvement in revenues there also.

IMO at least 4 of the Top 20 USA Hospitals have signed HUP deals with LIDCO

I expect more will sign in the next 12 months.









LiDCO Group Plc Pre-Close Trading Update and Notice of Results

20/02/2019


LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close update for the full year ended 31 January 2019 (FY19).

LiDCO continues to make progress with its HUP offering.
Since its launch 18 months ago, as of 19 February 2019 the Company had a total global contracted base of 191 HUP monitors (31 January 2018: 96) generating GBP1.50m (31 January 2018: GBP0.73m) of annualised HUP contracts with the revenue recognition being spread over the term of the contract.

Since the December 2018 trading update, LiDCO has gained a further two new US HUP customers, with the US contracted base as at 19 February standing at 114 monitors (2018: 58 units) worth GBP0.96m per annum.

These two new HUP customers are prestigious reference accounts and bring the total number of customers won during the FY19 to 13.

As detailed in the December update, the transitioning of the Company's larger UK customers to the SaaS business model has deferred revenue from the current financial year. Overall, LiDCO product revenues for FY19 were GBP6.19m (FY18: GBP6.87m) and total revenues (including third party products) were GBP7.32m (FY18: GBP8.27m). Whilst total revenues were marginally below market expectations, much of the effect of this on the bottom line is mitigated by favourable LiDCO product mix generating higher gross margins and overheads before share-based payments being approximately GBP0.28m lower than expected.

In the US, the strong growth of HUP meant that recurring revenues, which includes per patient disposables and service contracts, grew nearly 50% compared with the prior year to GBP1.27m (FY18: GBP0.85m). LiDCO product revenues for FY19 were GBP1.38m (FY18: GBP1.36m), with the prior year having exceptionally strong capital sales.

In the UK, LiDCO is seeking to convert its largest customers to the HUP business model.
The Company initially evaluated this approach with its largest UK account in January 2018 and, encouragingly, the customer has been able to treat more patients and has increased its investment in hemodynamic monitoring.

Following this success, three more of LiDCO's larger customers have signed multi-year HUP contracts, meaning that a total of GBP0.51m, or 15% of LiDCO's FY19 recurring revenues in the UK, have been converted.

This strategy, to actively convert UK customers to the SaaS business model, had a transitional impact on sales revenue recognition within the financial year through the deferral of revenues which would normally have been booked in the year.
These deferred revenues will be recognised over the 12 months from signing the HUP agreements. The transition to HUP has also dampened Q4 sales, as some customers have reduced purchases of consumables in anticipation of converting to HUP in their new financial year, which commences in April 2019. Demand for capital monitor purchases has also been lower than expected as customers conserved or diverted cash as part of their Brexit mitigation measures.
As a result, sales in Q4 were less than the usual peak and LiDCO product revenues for FY19 were GBP3.56m (FY18: GBP4.14m).

Following the previously announced termination of the Argon distribution contract and subsequent signing of new third-party opportunities, third party sales in FY19 were GBP1.13m (FY18: GBP1.40m). During FY19, the Company has sourced alternative distribution opportunities to replace the contribution made by Argon.
The Company has recently signed an exclusive UK distribution agreement with Xavant Technology (Pty) Ltd. ("XAVANT") to take full distribution responsibilities for Xavant's Advanced Nerve Stimulation and Monitoring Technology in the UK as from 1 February 2019. Xavant is a leading supplier of quantitative neuromuscular monitoring for use during general anaesthesia.

LiDCO is now the exclusive distributor for Maicuff, Antmed and Xavant in the UK.

Overall LiDCO revenues outside of the UK and US markets in FY19 were GBP1.25m (FY18: GBP1.37m). Strong revenue growth in Japan and preliminary orders from new distribution channels in Europe were offset by weaker demand from the Middle East region primarily driven by no sales to Iran, where the market has been impacted by US sanctions.

LiDCO continues to invest in geographical expansion, during the year applying for several regulatory registrations in key target markets in South East Asia and Latin America, which are expected to benefit FY20.

Importantly, the Company made significant progress with registering its latest monitor platform in China.

All the prerequisite testing and documentation was completed during 2018 with the submission to CFDA being made in January 2019.

The normal timescales for the CFDA to review this type of filing is a few months.

The Company's cash outflow in H2 was GBP0.32m compared with GBP1.19m in H1 and cash balances at 31 January 2019 totalled GBP1.72m (31 January 2018: GBP3.23m). The Company remains debt free and the Board believes that LiDCO retains the appropriate strength in its balance sheet to deliver its strategic objectives.

The Company intends to announce its results for the full year to 31 January 2019 on 26 March 2019.

Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said:

"Whilst the transition to the HUP business model has a short-term effect of deferring sales, we are encouraged by the progress made having built a recurring revenue base of over GBP1.5m in just 18 months from launch of the HUP business model.

The fundamentals of our business remain strong and we believe that this is reiterated by our new customer wins this financial year.

With continued focus on LiDCO's HUP model, we are well-placed to grow the business in line with our objectives over the short to medium term."

[willib2] 07/2/2019 18:04

Arf. Exactly, an aptitude for learning as against don't you ever learn.

[arf dysg] 07/2/2019 11:32

willib2, people who have money often have it in the family, ergo: Mummy and Daddy would have to give their dear child an expensive education, otherwise all the decent people would look down on them.

Caveat: "expensive" doesn't mean "good". Also, the quality of the teaching is useless if the pupil has no aptitude for learning.

[willib2] 06/2/2019 17:17

Arf re 9733 (Deltex)I can't imagine that ownership of such a financial sum of shares would warrant somebody equating that with an expensive education ( Mmmmm TC) know what I mean, and where would that leave NG. Haha

[trentendboy] 06/2/2019 09:51

Has the COUNT now gone over 3% in terms of his holding in Deltex?

[7767] 05/2/2019 15:07

I do not expect a wondrous statement as Matt Sassone said the America project was a bit slower than he hoped. However someone has just bought 500k shares so maybe there is something happening that we are not aware of yet.

[arf dysg] 05/2/2019 14:58

I can hold my breath until the 15th of February, but no longer!

[willib2] 04/2/2019 17:25

Arf, 2017 trading update 14thFeb results 28th March, 2018 Trading update 15thFeb results 10th April. Be patient my boy.

[arf dysg] 04/2/2019 16:31

Isn't it about time for LidCo to publish its year's revenue?

[trentendboy] 16/1/2019 15:22

Dire, utterly dire

[arf dysg] 28/11/2018 12:32

Tots amazeballsballsballsballs!

[arf dysg] 06/11/2018 18:14

Tots amazeballs!